CN100438861C - 含水2,6-二异丙基苯酚药物组合物 - Google Patents

含水2,6-二异丙基苯酚药物组合物 Download PDF

Info

Publication number
CN100438861C
CN100438861C CNB038180758A CN03818075A CN100438861C CN 100438861 C CN100438861 C CN 100438861C CN B038180758 A CNB038180758 A CN B038180758A CN 03818075 A CN03818075 A CN 03818075A CN 100438861 C CN100438861 C CN 100438861C
Authority
CN
China
Prior art keywords
formulation
present
amount
poloxamer
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038180758A
Other languages
English (en)
Chinese (zh)
Other versions
CN1671367A (zh
Inventor
张忠
O·阿尔马森
陈红敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transform Pharmaceuticals Inc
Original Assignee
Transform Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transform Pharmaceuticals Inc filed Critical Transform Pharmaceuticals Inc
Publication of CN1671367A publication Critical patent/CN1671367A/zh
Application granted granted Critical
Publication of CN100438861C publication Critical patent/CN100438861C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB038180758A 2002-07-29 2003-07-29 含水2,6-二异丙基苯酚药物组合物 Expired - Fee Related CN100438861C (zh)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US39949002P 2002-07-29 2002-07-29
US60/399,490 2002-07-29
US42219502P 2002-10-29 2002-10-29
US60/422,195 2002-10-29
US43697902P 2002-12-30 2002-12-30
US60/436,979 2002-12-30
US46245003P 2003-04-11 2003-04-11
US60/462,450 2003-04-11
US46431403P 2003-04-21 2003-04-21
US60/464,314 2003-04-21
US47040303P 2003-05-14 2003-05-14
US60/470,403 2003-05-14
US48535403P 2003-07-07 2003-07-07
US60/485,354 2003-07-07

Publications (2)

Publication Number Publication Date
CN1671367A CN1671367A (zh) 2005-09-21
CN100438861C true CN100438861C (zh) 2008-12-03

Family

ID=31192580

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038180758A Expired - Fee Related CN100438861C (zh) 2002-07-29 2003-07-29 含水2,6-二异丙基苯酚药物组合物

Country Status (14)

Country Link
US (1) US7915317B2 (https=)
EP (1) EP1539122B1 (https=)
JP (3) JP2005538191A (https=)
KR (1) KR101145692B1 (https=)
CN (1) CN100438861C (https=)
AU (1) AU2003261274C1 (https=)
BR (1) BR0313060A (https=)
CA (1) CA2494297C (https=)
HR (1) HRP20050182A2 (https=)
MX (1) MXPA05001061A (https=)
NZ (1) NZ538255A (https=)
PL (1) PL375874A1 (https=)
RS (1) RS54275B1 (https=)
WO (1) WO2004010941A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220283A1 (en) * 2002-07-29 2004-11-04 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
BR0313060A (pt) 2002-07-29 2005-06-28 Transform Pharmaceuticals Inc Composições farmacêuticas aquosas de 2,6-diisopropilfenol
AU2003286725B2 (en) * 2002-10-29 2007-07-12 Transform Pharmaceuticals, Inc. Propofol with cysteine
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
MXPA06013437A (es) 2004-05-19 2007-03-23 Los Angeles Biomed Res Inst Uso de un detergente para la eliminacion no quirurgica de grasa.
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
DE102004045622A1 (de) * 2004-09-17 2006-03-30 Aquanova German Solubilisate Technologies (Agt) Gmbh Konservierungsmittel-Zusammensetzungen
WO2007128866A2 (en) * 2006-05-09 2007-11-15 Novobion Oy Novel chemical compositions
US8197499B2 (en) * 2006-06-21 2012-06-12 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for joining non-conjoined lumens
US8608760B2 (en) * 2006-06-21 2013-12-17 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for joining non-conjoined lumens
CA2656179A1 (en) * 2006-06-21 2007-12-27 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for joining non-conjoined lumens
WO2008092084A2 (en) * 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
WO2009086206A2 (en) * 2007-12-20 2009-07-09 Synvascular, Inc. Compositions and methods for joining non-conjoined lumens
CN101977619B (zh) 2008-02-15 2013-06-05 诺沃百欧公司 姜黄素的可溶性复合物
US8563037B2 (en) * 2009-02-06 2013-10-22 Tautona Group, L.P. Compositions and methods for joining non-conjoined lumens
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
AU2011234492B2 (en) 2010-04-01 2014-02-27 Palette Life Sciences AB Thermogelling anaesthetic compositions
WO2012047870A2 (en) * 2010-10-05 2012-04-12 The Medicines Company Antimicrobial preservation of propofol emulsions
PL2627173T5 (pl) * 2010-10-12 2019-11-29 Chiesi Farm Spa Formulacje emulsyjne klewidypiny zawierające środki przeciw mikrobom
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
MX363465B (es) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Tratamiento de la grasa submental.
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
GB201106031D0 (en) 2011-04-08 2011-05-25 Highway Resource Solutions Ltd Adaptions to a lantern
US20180022698A1 (en) 2014-10-16 2018-01-25 The Board Of Trustees Of The Leland Stanford Junior University Novel methods, compounds, and compositions for anesthesia
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
CN106581737B (zh) * 2017-01-06 2019-09-06 哈尔滨鼓润生物技术有限公司 一种止血组合物及其制备方法
WO2018225229A1 (en) * 2017-06-08 2018-12-13 Terumo Kabushiki Kaisha Parenteral aqueous pharmaceutical composition
JP2022526976A (ja) * 2019-04-05 2022-05-27 ソレント・セラピューティクス・インコーポレイテッド カンナビジオール医薬組成物
CN114601800B (zh) * 2021-09-28 2023-07-28 天津瑞普生物技术股份有限公司 一种甲磷丙泊酚钠无菌粉针剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1356896A (zh) * 1999-06-21 2002-07-03 健一制药株式会社 用于静脉注射的含有普鲁泊福的麻醉组合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798846A (en) * 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US5296161A (en) * 1986-06-09 1994-03-22 The Clorox Company Enzymatic perhydrolysis system and method of use for bleaching
ES2140408T3 (es) * 1991-03-19 2000-03-01 Cytrx Corp Copolimeros de polioxipropileno/polioxietileno con actividad biologica mejorada.
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US5731356A (en) * 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
US5635540A (en) * 1994-12-09 1997-06-03 The University Of Virginia Patent Foundation Stabilized topical pharmaceutical preparations
AU6708096A (en) 1995-09-18 1997-04-09 Vesifact Ag Propofol nanodispersions
US6077545A (en) * 1995-10-30 2000-06-20 Matrix Pharmaceuticals, Inc. Process and composition for therapeutic cisplatin (CDDP)
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
US20020107291A1 (en) * 1997-05-26 2002-08-08 Vincenzo De Tommaso Clear, injectable formulation of an anesthetic compound
US5962536A (en) * 1998-07-31 1999-10-05 Komer; Gene Injectable propofol formulations
DE69912441T2 (de) * 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
US6150423A (en) 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
US6140373A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
GB2359747B (en) * 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
EP1289518A2 (en) 2000-05-25 2003-03-12 AstraZeneca AB Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent
EP1292282A2 (en) 2000-06-16 2003-03-19 RTP Pharma Inc. Improved injectable dispersions of propofol
IN187686B (https=) 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
IN188917B (https=) 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
EP1383445A4 (en) 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
GB0120702D0 (en) 2001-08-24 2001-10-17 Maelor Pharmaceuticals Ltd Anaesthetic formulations
GB0124071D0 (en) * 2001-10-08 2001-11-28 Kbig Ltd Improvement in the administration of high boiling point aneasthetics
US20040220283A1 (en) * 2002-07-29 2004-11-04 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
BR0313060A (pt) * 2002-07-29 2005-06-28 Transform Pharmaceuticals Inc Composições farmacêuticas aquosas de 2,6-diisopropilfenol
KR100482269B1 (ko) 2002-10-08 2005-04-14 센츄론(주) 2,6-디이소프로필페놀을 활성성분으로 하는 수용액상의마취용 주사제 및 그 제조방법
US8476010B2 (en) * 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1356896A (zh) * 1999-06-21 2002-07-03 健一制药株式会社 用于静脉注射的含有普鲁泊福的麻醉组合物

Also Published As

Publication number Publication date
KR101145692B1 (ko) 2012-05-25
US7915317B2 (en) 2011-03-29
US20050027019A1 (en) 2005-02-03
CA2494297A1 (en) 2004-02-05
AU2003261274B2 (en) 2008-07-31
EP1539122A4 (en) 2010-03-10
EP1539122A2 (en) 2005-06-15
RS20050066A (sr) 2007-09-21
CA2494297C (en) 2011-10-18
KR20050026539A (ko) 2005-03-15
RS54275B1 (sr) 2016-02-29
JP2005538191A (ja) 2005-12-15
AU2003261274A1 (en) 2004-02-16
WO2004010941A3 (en) 2004-06-17
WO2004010941A2 (en) 2004-02-05
HK1077515A1 (en) 2006-02-17
JP2011144161A (ja) 2011-07-28
MXPA05001061A (es) 2005-10-05
AU2003261274C1 (en) 2009-02-12
HRP20050182A2 (en) 2006-11-30
CN1671367A (zh) 2005-09-21
JP2014058553A (ja) 2014-04-03
BR0313060A (pt) 2005-06-28
EP1539122B1 (en) 2014-01-29
PL375874A1 (pl) 2005-12-12
NZ538255A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
CN100438861C (zh) 含水2,6-二异丙基苯酚药物组合物
EP1238677B1 (en) Parenteral fat emulsions comprising edetate as preservative
US8133918B2 (en) Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
US5731355A (en) Pharmaceutical compositions of propofol and edetate
US20040220283A1 (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US7125909B2 (en) Sterile parenteral nutrition compositions
EP1556022A1 (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
HK1077515B (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US20060189700A1 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081203

Termination date: 20210729

CF01 Termination of patent right due to non-payment of annual fee